Polyethyleneglycol-modified lipid compounds and uses thereof

摘要

Polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates are disclosed which have increased stability over commonly used PEG-lipids conjuguates. Liposomal compositions, stabilized plasmid-lipid particles (SPLP) and stabilized nucleic acid-lipid particles (SNALP) comprising said PEG-DAA conjuguates, for delivery of a bioactive agent to a cell or patient are described. Particularly disclosed are PEG-DAA conjugates of formula (I), wherein R1 and R2 are independently selected and are alkyl groups having from about 10 to about 20 carbon atoms; PEG is a polyethyleneglycol, wherein the terminal hydroxyl group is substituted with a methyl group; and L is a carbamate linker moiety.